Bristol-Myers Squibb Company (NYSE:BMY): Deutsche Bank believes Amylin (NASDAQ:AMLN) is a good strategic fit for Bristol-Myers (NYSE:BMY) and estimates that in 2016, the deal could be 5% accretive. The company raised its price target for Bristol-Myers shares from $37.50 to $39.00. They maintain a Buy rating on the name.
Barclays PLC (NYSE:BCS): According to Track Data, Barclays overall option implied volatility of 57, is above its 26-week average of 47. This large price movement coincides with the resignation of Chairman Marcus Agius and Chief Executive Bob Diamond, which will be announced before Parliament’s Treasury Select Committee on this Wednesday July 4.
Gildan Activewear Inc. (NYSE:GIL): Citigroup believes that Gildan Activewear will have a difficult time reaching its goal for 2012. They reiterate a Sell rating on their stock.
Check Point Software Technologies Ltd. (NASDAQ:CHKP): Estimates and Price target for Check Point has been lowered, as Jefferies cited a softer demand environment and the company’s exposure to the European market. The firm is cautious on Check Point near-term as there is some concern about the pricing of shares. Jefferies keeps a Buy rating on the name.
VMware, Inc. (NYSE:VMW): After its channel checks yielded mixed results, Jefferies lowered its price target for VMware (NYSE:VMW). The company believes its channel expectations for 2012 growth are lower and has seen signs that Microsoft (NASDAQ:MSFT) is taking a market share. Jefferies keeps a Hold rating on shares of VMware.
Don’t Miss: Apple: A Rebel Without A Clause.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.